IMMUNOLOGY. For the article “CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ” by Dominik Mumberg, Paul A. Monach, Sherry Wanderling, Mary Philip, Alicia Y. Toledano, Robert D. Schreiber, and Hans Schreiber, which appeared in number 15, July 20, 1999, of Proc. Natl. Acad. Sci. USA (96, 8633–8638), the authors note the following change. In Table 4, due to a printer's error, the last entry in the third column was incorrectly entered as 2/12. The correct entry is 2/2. A corrected Table 4 is shown below.
Table 4.
LNC from mL9-immunized mice reject tumor cells made insensitive to IFN-γ (PRO-DNγR), but still require IFN-γ for this effect
| LNC* | Antibody treatment† | Tumor incidence after 28 days‡ |
|---|---|---|
| − | − | 5/5 |
| + | − | 0/5 |
| + | Anti-IFN-γ | 2/2 |
SCID mice were inoculated s.c. with PRO-DNγR tumor cells and received LNC from mL9-immunized mice.
† An additional animal treated with LNC and also with anti-IL-4 antibody rejected the tumor cell challenge similar to the LNC-treated mice treated with anti-IL-4 in Table 3.
‡ The tumor incidence of PRO-DNγR for LNC-treated versus untreated mice was statistically significant (P value = 0.008) by Fisher's Exact test. The difference between tumor incidence for LNC-treated and LNC-treated plus anti-IFN-γ antibody is also statistically significant (P value = .048) by Fisher's Exact test.